The right biotech marketing agency is the one built for your business model and your regulatory exposure, not the one at the top of a “best agencies” list. A company selling research-use-only reagents, a platform company courting pharma partners, and a clinical-stage therapeutics company with public shareholders need three different kinds of help, and they work under three different sets of rules. Get that match right first. Channels, creative and price come second.
Most pages ranking for this search are agency sales pages or roundups that rank agencies by size and service list. They rarely tell a founder which job to hire for, which rules shape every sentence the agency writes, or how to test a pitch team before signing a retainer. This guide does. It is written for biotech CEOs, founders and first marketing leads at early and growth-stage companies.
Need senior marketing leadership without a full-time hire? See CO Consulting’s fractional CMO services.
First, decide which biotech marketing job you are hiring for
“Biotech” covers companies whose buyers, sales cycles and legal limits have almost nothing in common. Before you take a single agency call, find your row in the table below. It tells you who you are really marketing to, what the work produces, and the profile of agency that fits.
| Your company | Who decides | What marketing has to produce | Rule that shapes the copy most | Agency profile that fits |
|---|---|---|---|---|
| Research tools, reagents, instruments (often RUO) | Bench scientists, lab managers, core facility heads, procurement | Search traffic on methods and assays, application notes, demos, quote requests | RUO labeling and intended-use rules | Scientific content plus B2B demand generation, comfortable with ecommerce and distributors |
| CRO, CDMO and lab services | Biotech and pharma program leads, outsourcing and sourcing teams | Credibility assets, case data you can disclose, a short list of target accounts warmed up before conferences | Client confidentiality and contract terms | Account-based marketing and conference programs |
| Platform or partnering biotech | Pharma business development, search and evaluation, alliance teams | A partnering narrative, data packages, meetings booked at partnering events | Confidentiality agreements; Reg FD if you are public | Corporate positioning and BD storytelling, not lead volume |
| Private, pre-commercial therapeutics | Investors, potential partners, clinical investigators, future hires | Clear corporate story, scientific presence at meetings, a website that survives diligence | 21 CFR 312.7: no promotional safety or efficacy claims for an investigational drug | Corporate communications and scientific PR, with medical review built in |
| Public, clinical-stage biotech | Analysts, investors, partners, investigators, patient communities | Disclosure-ready news flow, conference data releases, investor materials | Regulation FD, securities offering rules, plus 312.7 | IR and corporate comms experience working alongside your securities counsel |
Two patterns show up again and again. Tools companies hire a PR-led agency and get coverage with no pipeline. Therapeutics companies hire a demand-generation shop and get lead forms nobody should be filling in. If you are moving from research tools toward a cleared diagnostic, the playbook changes again, and our guide to medical device marketing strategy covers that shift.
The rules a biotech marketing agency has to work inside
An agency that cannot explain these rules in plain English on the first call is not a biotech marketing agency, whatever its website says. You do not need it to act as your lawyer. You need it to know where the lines are so drafts arrive close to compliant and your counsel’s review is a check, not a rewrite.
| Rule | Applies to | What it means for marketing | Who should sign off |
|---|---|---|---|
| 21 CFR 312.7(a) | Sponsors of investigational drugs and anyone acting for them, including agencies | You may not “represent in a promotional context that an investigational new drug is safe or effective.” The rule does not restrict the full exchange of scientific information, so data at a scientific meeting is fine; a website headline calling your candidate “a safe, effective new option” is not. | Regulatory affairs and counsel |
| FDCA 502(gg), added by the Consolidated Appropriations Act, 2023 | Pre-approval communications to payors, formulary committees and similar entities | Allows sharing product information such as the indication being studied, the anticipated approval timeline, pricing and factual study results, with required disclosures. FDA issued an updated draft guidance in June 2026, according to a June 17, 2026 legal analysis. Its recipients are payors and similar entities, so it is not a route to promote to prescribers. | Regulatory, market access, counsel |
| 21 CFR 809.10(c)(2)(i) and FDA’s November 2013 RUO/IUO guidance | Tools and assay companies selling research-use-only products | Labeling must say “For Research Use Only. Not for use in diagnostic procedures.” FDA looks at the totality of circumstances, and commentary on the final guidance flags sales calls to clinical labs and clinical-validation support as signs of a clinical intended use. Ads, webinars and slide decks that talk about patient results can undercut the RUO label. | Quality/regulatory |
| Regulation FD, 17 CFR 243.100 | Public companies and people acting on their behalf | Material nonpublic information shared with covered recipients such as analysts and shareholders must be made public at the same time (intentional) or promptly (unintentional). An agency drafting investor decks or briefing reporters is acting on your behalf. | CFO, general counsel |
| SEC 2013 report on social media | Public companies using LinkedIn, X or executive accounts | Social channels can be used for material announcements only if investors were told in advance which channels the company will use. An executive’s personal post with fresh data is a Reg FD problem waiting to happen. | General counsel, IR |
| SEC Rule 163B (2019) | Any issuer considering a registered offering, such as an IPO | Lets you “test the waters” before or after filing, but only with qualified institutional buyers and institutional accredited investors. Around an offering, all public marketing should go through securities counsel first. | Securities counsel, bankers |
| Meeting embargo policies, for example AACR’s | Anyone presenting data at a scientific meeting | Abstracts are confidential until the meeting posts them. Breaking the embargo can jeopardize the abstract’s place in the program. | Medical affairs, comms lead |
Rewrite test: the same idea, said safely
Here is a practical way to judge an agency’s regulatory instinct. Give the pitch team the left column and ask them to fix it. Good teams land near the right column without being told why.
| Draft line (risky) | Why it is a problem | Safer version |
|---|---|---|
| “XB-101 is a safe, well-tolerated treatment that shrinks tumors.” | Promotional safety and efficacy claim for an investigational drug (312.7) | “XB-101 is an investigational therapy being studied in a Phase 2 trial. Its safety and effectiveness have not been established.” |
| “Our assay helps oncologists pick the right therapy for every patient.” | Clinical claim for an RUO product | “For Research Use Only. Not for use in diagnostic procedures. Built for translational researchers profiling tumor samples.” |
| CEO LinkedIn post: “Just saw our interim readout. Wow.” | Possible selective disclosure of material information (Reg FD) | No post until the data is released through the company’s announced disclosure channels; then share the release. |
| Press release with full abstract data the week before the meeting posts it | Breaks the meeting embargo | Title-and-logistics release when titles post; data release at the embargo time the meeting sets. |
The product name and copy above are illustrative examples written for this guide, not taken from any real company.
Biotech digital marketing by audience: what to do, and what to stop
Life science marketing works audience by audience. Each group has a different job and a different reason to trust you. Here is how the work splits, with the common waste to cut.
Bench scientists and lab managers
Scientists search for methods, protocols and troubleshooting, not for your brand. The content that earns their attention looks like their own work: application notes with real conditions and data, protocols, posters turned into web pages, and technical webinars where your application scientist answers questions live. A strong webinar marketing strategy often outperforms paid ads for tools companies because it puts your expert in front of the exact people who would run the experiment.
Stop doing: brand campaigns with stock photos of pipettes, and gated PDFs that ask for a phone number before a scientist can see the protocol. Ungate the method, gate the deeper dataset or the sample request.
Procurement and core facility heads
Once a scientist wants your product, someone still has to buy it. Make that easy: clear catalog numbers, a quote request that does not require a sales call, documentation for vendor onboarding, and listings with the distributors your buyers already use. These are unglamorous pages, but they often decide whether a trial order happens this quarter.
Pharma business development partners
For platform companies and CROs, the market might be a few dozen named companies. That is account-based work, and it is different from lead generation. Build a short list, map the people in search and evaluation and in the relevant therapeutic area, and warm them up before partnering meetings. Our guide to account-based marketing strategy covers the full method.
One practical catch: LinkedIn’s company list upload needs at least 300 rows and must match at least 300 member accounts to run, and LinkedIn recommends 1,000 or more companies. A 40-company pharma target list will not upload as a list on its own. Ask any agency pitching LinkedIn ABM how it plans to reach a list that small. A vague answer tells you it has mostly run high-volume B2B campaigns.
Investors and analysts
Your website is read during diligence more often than you think. Investors want a clear pipeline or product chart, a team page with credentials, publications, and a newsroom that is current. For public companies, every investor-facing asset is also a Reg FD asset, so the agency’s drafts should go through the same disclosure review as your press releases.
Physicians and patients, later
Only a company with an approved product, or one getting close to launch, needs HCP and patient marketing. That work has its own rulebook, and our guide to pharmaceutical marketing covers it. If an agency pitches a pre-clinical company a patient awareness campaign, ask what exactly it plans to say.
Plan the year around the scientific meeting calendar
For oncology-adjacent and partnering biotechs, the marketing year runs on meeting deadlines. The dates below are from the organizers’ own pages. Build backward from them, because the work that matters happens weeks before you fly.
| Date | Milestone | Marketing work due |
|---|---|---|
| November 10, 2026 | AACR 2027 regular abstract deadline | Agree which data you will present and who owns the poster |
| January 6, 2027 | AACR late-breaking and clinical trials abstract deadline | Draft the release plan for each possible outcome |
| March 2, 2027, 4:30 p.m. ET | AACR regular abstracts and late-breaking titles post | Release on regular abstract data; title-only release for late-breakers; book meetings with target accounts |
| April 2 to 7, 2027 | AACR Annual Meeting, Orlando | Late-breaking data release at the posted embargo time; poster and booth follow-up |
| June 7 to 10, 2027 | BIO International Convention, Philadelphia | Partnering meetings; one-page non-confidential deck; BD outreach starting weeks earlier |
ASCO’s Annual Meeting, held in Chicago in early June, overlaps with BIO season for oncology companies, so confirm its dates and embargo rules on ASCO’s site and plan both together. For each major meeting, a workable run of steps looks like this:
- Eight weeks out: pick the one message the meeting should prove, and list the 20 to 50 people you most want to meet.
- Six weeks out: send personal outreach to that list, with the session or booth details and a reason to meet.
- Four weeks out: prepare the release, the web version of the poster, a short summary for social, and the follow-up email, all marked with the embargo time.
- Two weeks out: legal and regulatory review of every asset, including the booth graphics and the slide your CEO may show at a side event.
- Meeting week: publish at the embargo time, not before. Capture who you met and what they asked in your CRM the same day.
- Two weeks after: send the follow-up, publish the poster as a web page, and report on meetings held and next steps agreed, not booth scans.
How to choose a life science marketing agency: a weighted scorecard
Agency pitches look alike. A scorecard forces you to compare them on what predicts a good engagement. Score each agency from 1 to 5 on every row, multiply by the weight, and compare totals. The weights are my suggestion for an early-stage company; adjust them to your row in the first table.
| Criterion | Weight | What a 5 looks like | Question to ask |
|---|---|---|---|
| Business model fit | 25% | Has served companies like yours (tools, services, platform or therapeutics) at your stage | “Show me two clients with our model and stage, and what you did in the first 90 days.” |
| Scientific depth | 20% | The people writing your content can read your data; a named scientific reviewer | “Who on the team has worked at the bench or in medical affairs, and will they write or only review?” |
| Regulatory instinct | 15% | Passes the rewrite test above without prompting; has a review workflow | “Walk me through how a draft gets from your writer to our counsel.” |
| Measurement | 15% | Reports on qualified opportunities, meetings booked and pipeline, not impressions | “What will your month-three report show, and what number will you hold yourselves to?” |
| Team continuity | 10% | The people in the pitch are the people on the account | “Who exactly works on our account, and what share of their time is ours?” |
| Commercial terms | 10% | Short initial term, clear exit, you own all accounts and assets | “What is the notice period, and who owns our ad accounts, website and content?” |
| Conference and PR experience | 5% | Has run embargoed data releases and partnering meetings | “Describe the last embargoed release you ran and what went wrong.” |
Red flags worth walking away over: promises of specific rankings or lead counts, consumer-style hype in their sample work, no answer on who reviews scientific accuracy, and a refusal to let you own your own ad accounts. Ask for a writing sample on a topic close to yours, and read it with your most skeptical scientist. If you want to see what strong educational content looks like in practice, these content marketing examples are a useful benchmark for tone and depth.
What a biotech marketing agency costs, and what each budget level can buy
Most agencies do not publish prices. One life science specialist that does says clients should expect at least $5,000 a month for professional services plus at least $2,000 in media spend. Treat that as one agency’s floor, not an industry average. Fees mostly come in three shapes: a monthly retainer for ongoing work, a fixed project such as a website rebuild or a conference launch kit, or a base retainer with project add-ons around big moments.
Rather than chase a benchmark, match the scope to the money:
- Below a specialist’s minimum: buy one project, not a retainer. A diligence-ready website, or a conference kit for your most important meeting, does more than a thin retainer spread over six channels.
- Around a specialist’s floor: one workstream done well, for example scientific content and search for a tools company, or corporate communications for a private therapeutics company.
- Multiple workstreams: content, paid media, conferences and PR run together. At this level, insist on one accountable lead and one pipeline report across everything.
Whatever you spend, define success before you sign. For a tools company, that might be quote requests and trial orders. For a platform company, partnering meetings and term-sheet conversations. For a therapeutics company, clean coverage of a data release and a website investors trust. None of those is “impressions.”
Agency, fractional CMO or first marketing hire?
An agency executes. It does not decide your positioning, choose between a partnering story and a product story, or tell your board which bet to make. Many early biotechs hire an agency before anyone inside owns the strategy, then spend months reviewing work that answers the wrong question.
A simple way to sequence it: if you do not yet know which row of the first table you are in for the next two years, get strategy first, from a fractional CMO or an experienced advisor. Once the plan and the measures are clear, hire the agency to run it. Hire a full-time marketing lead when the volume of work, and the internal coordination with medical, regulatory and IR, needs someone in the building every day. If you want a second opinion on where you are in that sequence, you can book a consultation and we can work through the scorecard together.
In my view, the best biotech marketing agency relationships start with a narrow brief, a 90-day plan tied to one commercial goal, and a regulatory review process both sides agreed in writing. Start there, and the agency you pick has a fair chance of doing its best work.
Work with CO Consulting
Senior marketing leadership, without the full-time hire
- One senior owner of strategy, budget, vendors and the weekly scorecard
- Audit first, then a prioritized 90-day plan with measurable milestones
- Weekly team leadership, monthly strategic reviews and quarterly planning
- No guarantees we cannot back up; reporting tied to pipeline
Frequently asked questions
What does a biotech marketing agency do?
A biotech marketing agency plans and produces marketing for life science companies: scientific content such as application notes and webinars, websites, search and paid media, conference programs, PR and investor-facing materials. The best ones also know the rules that limit biotech claims, such as FDA limits on promoting investigational drugs, research-use-only labeling and, for public companies, SEC Regulation FD, so drafts arrive close to compliant.
How much does a biotech marketing agency cost?
Most agencies quote privately, but one life science specialist publishes a floor of about $5,000 a month in fees plus at least $2,000 in media spend. Fees usually come as a monthly retainer, a fixed project such as a website or conference kit, or a hybrid. If your budget is below an agency's minimum, buy one well-scoped project instead of a thin retainer.
Can a pre-clinical or clinical-stage biotech do marketing at all?
Yes, within limits. Under 21 CFR 312.7 a sponsor may not represent in a promotional context that an investigational drug is safe or effective, but the rule does not restrict the full exchange of scientific information. Corporate communications, scientific presentations, investor materials, recruiting and partnering outreach are all possible, as long as copy avoids promotional safety or efficacy claims and goes through regulatory review.
Should a biotech startup hire an agency or a marketing lead first?
If you have not yet settled positioning, target audience and what success means, get strategy first from a fractional CMO or experienced advisor, then hire an agency to execute a defined plan. A full-time marketing lead makes sense once the volume of work and the coordination with medical, regulatory and investor relations need someone inside the company every day.
How is life science marketing different from general B2B marketing?
Buyers are scientists who judge you on data, sales cycles are long, and several groups decide together: the scientist, the lab manager, procurement and sometimes a pharma partner team. Claims are regulated, conference embargoes control timing, and public companies must follow disclosure rules. Content that looks like real scientific work usually beats brand campaigns.
How do I measure whether a biotech marketing agency is working?
Agree the measures before you sign and tie them to your model. A tools company might track quote requests, sample requests and trial orders. A platform company might track partnering meetings and follow-up conversations with target accounts. A therapeutics company might track coverage of data releases and investor engagement. Impressions and follower counts alone rarely show whether the work is paying off.
More Growth Consulting guides
- How to Build an Account Based Marketing Strategy
- What Is B2B Marketing? Modern Definition
- Unique Selling Proposition (USP): Definition, Formula, and Examples
- Account-Based Marketing for Service Businesses
- The Best Client Management Apps for Service Businesses (2026)
- Business Marketing Solutions: The Category Map and How to Assemble the Right Mix
- All Growth Consulting guides →